Molecular structure of Lenalidomide, CAS Number: 191732-72-6
Lenalidomide (CAS 191732-72-6)
See product citations (18)
Alternate Names:
(3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; Revlimid
Application:
Lenalidomide is a thalidomide analog known to have immunomodulatory properties
CAS Number:
191732-72-6
Purity:
≥99%
Molecular Weight:
259.26
Molecular Formula:
C13H13N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lenalidomide is a thalidomide analog known to inhibit TNF-alpha secretion and possess immunomodulatory properties. In vitro studies have been conducted on Lenalidomide to examine its impact on cell proliferation, apoptosis, and angiogenesis. These investigations have revealed its ability to impede the growth of various cancer cells, alongside its capacity to induce apoptosis and regulate angiogenesis.
Lenalidomide (CAS 191732-72-6) References
- SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. | Barosi, G., et al. 2012. Ann Hematol. 91: 875-88. PMID: 22476884
- Lenalidomide for treatment of myelodysplastic syndromes. | Komrokji, RS. and List, AF. 2012. Curr Pharm Des. 18: 3198-203. PMID: 22571699
- Drug-induced interstitial pneumonitis due to low-dose lenalidomide. | Kunimasa, K., et al. 2012. Intern Med. 51: 1081-5. PMID: 22576392
- Lenalidomide in solid tumors. | Segler, A. and Tsimberidou, AM. 2012. Cancer Chemother Pharmacol. 69: 1393-406. PMID: 22584909
- The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). | Dawar, R. and Hernandez-Ilizaliturri, F. 2012. Best Pract Res Clin Haematol. 25: 185-90. PMID: 22687454
- Lenalidomide maintenance for multiple myeloma. | Brower, V. 2012. Lancet Oncol. 13: e238. PMID: 22833889
- Lenalidomide-associated hepatotoxicity--a case report and literature review. | Nojkov, B., et al. 2012. Anticancer Res. 32: 4117-9. PMID: 22993370
- Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. | Jan, M., et al. 2021. Sci Transl Med. 13: PMID: 33408186
- Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. | Bachy, E., et al. 2022. Blood. 139: 2338-2346. PMID: 34936697
- Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. | Li, X., et al. 2022. Int Immunopharmacol. 103: 108470. PMID: 34952465
- Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. | Tettamanti, S., et al. 2022. Leuk Lymphoma. 63: 1566-1579. PMID: 35259043
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. | de Tute, RM., et al. 2022. J Clin Oncol. 40: 2889-2900. PMID: 35377708
- Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison. | Cordoba, R., et al. 2022. Adv Ther. 39: 2668-2687. PMID: 35403948
Inhibitor of:
β-2-Microglobulin, 1700008O03Rik, 9530053A07Rik, AHSP, AL, Apg12, APRIL-TWEAK, ARMC6, Arxes2, B lymphocytes, Baff, BAI-1, Bcl-11a, Bcl-7b, BTN3A2, BTN3A3, BZW1, C10orf131, C10orf72, C10orf81, C11orf51, C12orf62, C14orf147, C17orf107, C19orf22, C1orf62, C87499, C87977, CARD11, CD16, CD200R2, CD3EAP, CD79A, CD8α, CRBN, CS1, CUL-2, D5Ertd577e, DCAF15, DCAF17, Dcun1D1, Dcun1D4, Dectin-2, DTX3L, EG545802, EndoV, Erythroid lineage, F5 TCR α, F5 TCR β, Fbxw19, FBXW5, FCGR (Fc gamma receptor), FcRH1, FcRH2, FcRH3, FcRH4, FcRH6, FLJ44815, G-CSF, GATA-2, GILT, GIMAP1, GIMAP6, GP49B, H2-Eκ, Hemoglobin β, HLA-DP, HLA-F`, HSPC121, ICSBP, IFI-202, IFN-α12, Ig κ, Ig κ chain, Ig κ light chain, Ig λ, Ig λ chain V4A, Ig λ light chain, IgA chain C, IgD, IgD Chain C, IgG κ light chain, IgG Fab fragment, IgG light chain, IgH-VJ558, IgHg, IgM, Ikaros, IL-2R, IL-5R, Interferon inducible (IFI, IFIT), IRF-4, KIAA1984, KIR3DL2, KLHDC6, KLHL1, KLHL21, Klra22, LAT2, LHFP, ligatin, LOC100041241, LOC100041274, LOC100041448, LOC666187, LST1, Ly-49C, Ly-49E, Ly-49J, Ly-49L, Ly-49W, Ly6G6d, MAGE-A11, MAGE-A12, MAGE-C2, MAGE-H1, MIB1, MIC2, Might chain, MUM1, NKAPL, NKG2-E, Olr1630, Olr1704, Olr233, Olr500, Olr704, OTC, Paired Box (PAX), Pax-5, PAX9, PCNP, Pegasus, PHAPI2, PIGF-2, PILR-β, Plasma Cell, Plasmacytoid DC Marker, POLDIP3, PP2Cη, PPIAL4D, Proliferation Marker, QPCTL, Rbx1, RFXAP, RhCE, RNF113A2, RNF126, RNF150, RNF175, RNF220, RNF38, Rsl2, Rslcan-14, RSRC2, SFTPG, Siglec-H, SLURP-2, SPANX-A-E, T6BP, TAL1, TALL-1, TCL-6, TCR α, TCR δ, TCR V β, TNF alpha, TNFα-IP 2, TPO, Trap1a, Trav12n-1, TRIM34B, TRIM58, Tsga8, TTC30A2, TWEAK, UBCE7IP4, UBE3C, VpreB3, WDR21C, WDSOF1, WDYHV1, Xlr4, ZNF397OS, ZNF717, ZNF720, and ZNF730.Activator of:
ARHGAP18, ASB-8, Axotrophin, B7-H6, BAFF-R, BC061212, BCAP, BCMA, BCMP1, BTBD18, Bu-1a, c-IAP2, CD137L, CD16-A, CD20, CD223, CD3-ε, CD300LG, CD38, CD8β, CD94, Cdc53, CMTM7, CT47A12, CUL-5, DcR3, Dcun1D3, DOCK 2, E6-AP, EDRF1, Elf-1, FOG, GBP8, GIMAP5, GIMAP9, IFN-γRα, Ig λ chain, IGLL5, ILT-7, KIR3DL2, KIR3DL3, KLHL9, Klra22, KLRH1, LSP1, Ly-49B, Ly-49D, Ly49F, Lysozyme, MAGE-B3, MARCH3, MARCH8, Mill2, MLF2, Myeloid Marker, NK 2B4, NKLAM, PD-L2, Pdcd-1L2, Plasmacytoid DC Marker, RELL2, RFPL2, RNF141, RNF23, RNF25, SETBP1, SKAP55-R, Skeletrophin, Slfn, SOCS-2, TRIAD1, TRIM69, TROY, UBC12, UBC8, UBE2O, UBE2S, UBE2U, UBE2Z, UCH-L5, ULBP5, USP17L4, USP17L7, USP17L8, USP9Y, and WDR21A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lenalidomide, 10 mg | sc-218656 | 10 mg | $50.00 | |||
Lenalidomide, 100 mg | sc-218656A | 100 mg | $374.00 | |||
Lenalidomide, 1 g | sc-218656B | 1 g | $2071.00 |